Hyun-Min Yoon ^{1 *}, . The Editorial Board of Journal of Pharmacopuncture ²

retraction

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

The Editorial Office of Journal of Pharmacopuncture (JoP) received a report which is related to plagiarism issue by Leslie Lansman, the Global Permission Manager of SpringerNature. Accordingly, we began the inspection and found several plagiarized figures including Nature’s notifying. The corresponding author had explained that “This article is not a research but a review which is collected in already existing research and has appropriate refereces.” The authors of this article committed serious research misconduct. The editors of JoP are convinced an immediate, absolute retraction is needed. Therefore, we retract this manuscript. Also, we inform researchers and medicine community that the contents and results of this paper is invalid. We, the Editorial Board of Journal of Pharmacopuncture, seriously take this research ethics violation. We sincerely apologize to the reviewers, editors who devoted their time and endeavor to evaluate the article and medicine community.

1. Sabine Maria Bird. Investigating a potential role for irisin as a biomarker in the early detection of Alzheimer's disease [dissertion]. The University of Western Australia; 2018. 402p. DOI:10.4225/23/5b2af9560e3f7
2. Thomas G. Brock. Weight Loss: A New Star is Irisin [Internet]. Cayman Chemical; [cited 2020 March 26]. Available from: https://www.caymanchem.com/news/ weight-loss-and-irisin/ .
3. Perakakis N, Triantafyllou GA, Fernández-Real JM, Huh JY, Park KH, Seufert J, et al. Physiology and role of irisin in glucose homeostasis. Nature. 2017;13:324-37. DOI:10.1038/nrendo.2016.221
4. Xiong XQ, Chen D, Sun HJ, Ding L, Wang JJ, Chen Q, et al. FNDC5 overexpression and irisin ameliorate glucose/lipid metabolic derangements and enhance lipolysis in obesity. BBA Molecular Basis of Disease. 2015;1852(9):1867-75. DOI:10.1016/j.bbadis.2015.06.017
5. Liu TY, Shi CX, Gao R, Sun HJ, Xiong XQ, Ding L, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes. Clinical Science. 2015;129(10):839-50. DOI:10.1042/CS20150009
6. Sanchis-Gomar F, Perez-Quilis C. The p38–PGC-1α–irisin– betatrophin axis. Adipocyte. 2013;3(1):67-8. DOI:10.4161/ adip.27370